Compare Summit Therapeutics Inc (SMMT) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs VF Corp — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while VF Corp trades at $15 (market cap $5.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× VF Corp's market cap, and VF Corp pays a 2.48% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and VF Corp for 65 Days on average.
| SMMT | VFC | |
|---|---|---|
Market Cap | $13.71B | $5.71B |
Volume | 6,173,057 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $21.55 |
52-Week Low | $12.43 | $12.62 |
Typical Hold Time | 16 Days | 65 Days |
Enterprise Value | $13.04B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
VFC trades at $14.53, up 1.04% with a bullish technical signal despite recent earnings misses. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though net income is projected to recover to $274M in 2026. Valuation appears reasonable with P/E of 21.06 and P/S of 0.61, while analyst consensus leans Hold with a $18.33 price target.
The outlook remains cautious due to Vans brand weakness and execution risks, though cost-cutting and outdoor segment growth offer potential upside. Key risks include persistent revenue declines and high debt levels, while institutional sentiment is divided with 41% Buy ratings versus 52% Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
